NCT03968861

Brief Summary

The objective of this study is to document the outcome at 2-3 years of age of participants of the TOBY Xe trial, to provide preliminary information about the later clinical effects of treatment with Xenon gas combined with moderate hypothermia following perinatal asphyxia. The TOBY Xe trial was a randomised controlled trial of inhaled xenon gas combined with hypothermia for the treatment of perinatal asphyxia. The trial primary outcome was changes on magnetic resonance parameters examined prior to discharge from hospital. Continuing clinical follow-up of trial participants is important following any therapeutic trial and is essential in early phase trials where information on the clinical effects of the intervention are lacking. Therefore, we have set up this study to determine the major clinical and neurological outcomes of participants of the TOBY Xe trial and to determine whether the magnetic resonance parameters in that trial are qualified to predict outcome following neural rescue therapy. This information is necessary for planning further studies of this intervention.

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
69

participants targeted

Target at P25-P50 for all trials

Timeline
Completed

Started Aug 2014

Typical duration for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

August 1, 2014

Completed
2.8 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2017

Completed
11 months until next milestone

Study Completion

Last participant's last visit for all outcomes

May 1, 2018

Completed
1 year until next milestone

First Submitted

Initial submission to the registry

May 14, 2019

Completed
16 days until next milestone

First Posted

Study publicly available on registry

May 30, 2019

Completed
Last Updated

May 30, 2019

Status Verified

May 1, 2019

Enrollment Period

2.8 years

First QC Date

May 14, 2019

Last Update Submit

May 28, 2019

Conditions

Outcome Measures

Primary Outcomes (2)

  • Scores on Bayley scales of infant and toddler development

    Composite scores of the Cognitive, Language and Motor scales scaled to a metric, with a mean of 100, standard deviation of 15, and range of 40 to 160

    at 2-3 years of age

  • Relation between magnetic resonance markers and neurodevelopmental outcome

    Peak area Lactate/N Acetyl Aspartate ratio on magnetic resonance spectroscopy and fractional anisotropy on diffusion tensor magnetic resonance imaging

    at 2-3 years of age

Secondary Outcomes (1)

  • Grade of disability

    At 2-3 years of age

Other Outcomes (4)

  • Optimality Scores on Hammersmith neurological examination

    At 2-3 years of age

  • Gross Motor Function Classification System

    At 2-3 years of age

  • Manual Ability Classification System

    At 2-3 years of age

  • +1 more other outcomes

Study Arms (2)

Standard care with moderate hypothermia

Surviving children allocated to standard care with moderate hypothermia in the TOBY-Xe trial

30% Xenon for 24 hours combined with moderate hypothermia

Surviving children allocated to inhaled xenon combined with moderate hypothermia in the TOBY-Xe trial

Drug: Xenon

Interventions

XenonDRUG

Inhaled xenon gas given via purposely designed ventilator

Also known as: Lenoxe
30% Xenon for 24 hours combined with moderate hypothermia

Eligibility Criteria

Age2 Years - 3 Years
Sexall
Age GroupsChild (0-17)
Sampling MethodNon-Probability Sample
Study Population

The study population were the surviving participants in the TOBY Xenon study. There were 69 survivors from 92 participants at 2 years after birth and 62 of the 69 participants entered the TOBY Xenon Follow-up Study

You may qualify if:

  • Surviving participants in the TOBY Xenon study

You may not qualify if:

  • Lack of consent to participate

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Guys and St Thomas NHS Trust

London, United Kingdom

Location

Imperial College London NHS Healthcare Trust

London, United Kingdom

Location

University College London Hospital NHS Foundation Trust

London, United Kingdom

Location

MeSH Terms

Conditions

Brain Diseases

Interventions

Xenon

Condition Hierarchy (Ancestors)

Central Nervous System DiseasesNervous System Diseases

Intervention Hierarchy (Ancestors)

Noble GasesElementsInorganic ChemicalsGases

Study Officials

  • David A Edwards, FMedSci

    King's College London

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
PROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

May 14, 2019

First Posted

May 30, 2019

Study Start

August 1, 2014

Primary Completion

June 1, 2017

Study Completion

May 1, 2018

Last Updated

May 30, 2019

Record last verified: 2019-05

Locations